July 18, 2007 -- Two new studies identify the first gene variants associated with restless legs syndrome.
The studies appear in today's online editions of The New England Journal of Medicine and Nature Genetics.
Together, the studies pinpoint three common genetic variations that are linked to restless legs syndrome. The findings may lead to new treatments for restless legs syndrome, according to the researchers.
Other genes -- and environmental factors -- may also affect restless legs syndrome, in which people feel an irresistible urge to move their legs, particularly in the evening and at night.
Restless Legs Syndrome Genetics
The study published in The New England Journal of Medicine comes from doctors including Kari Stefansson, MD, PhD, of Decode Genetics in Reykjavik, Iceland, and David Rye, MD, PhD, an Emory University neurology professor.
They scanned the genes of 306 people in Iceland who have restless legs syndrome and more than 15,600 people in Iceland without restless legs syndrome.
The gene scans show that a certain variation in the BTBD9 gene was associated restless legs syndrome and other periodic limb movements during sleep.
The researchers confirmed that finding in follow-up gene studies in Iceland and the U.S.
The scientists don’t know exactly what the BTBD9 gene does. But their data suggest that eliminating that particular variation of the BTBD9 gene would wipe out half of the Icelandic and U.S. cases of restless legs syndrome that they studied.
"This is the most definitive link between genetics and RLS (restless legs syndrome) that has been reported to date," Rye says in an Emory University news release.
The study was partly funded by the Restless Legs Syndrome Foundation. Several of the researchers, including Rye and Stefansson, note ties to various drug companies or other financial interests in the topic.
The findings "offer hope to patients with periodic limb movements in sleep and RLS that the syndrome's pathophysiology [cause] will be understood and that such knowledge will lead to additional effective and durable treatments," writes editorialist John Winkelman, MD, PhD.
Winkelman works in the division of sleep medicine at Boston's Brigham and Women's Hospital and Harvard Medical School. His editorial appears in today's online edition of The New England Journal of Medicine.